Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder. Fair value range: low $176, high $337, with mid-point at $255.
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.
§1 Sintesi
Premium quality compounder with a wide competitive moat.
Reverse DCF implies ~20% perpetual growth required at current $450 price.
Intrinsic valuation models anchor at $254.67, signaling a massive premium.
Sell recommendation driven by extreme valuation disconnect, not business quality.
Fair value
$255
Margin of safety
-76.7%
Confidence
87/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$450.06Price
Low $175.51
Mid $254.67
High $336.56
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.
Massive installed base of da
Massive installed base of da Vinci systems
High switching costs for hospitals
High switching costs for hospitals and surgeons
Cycle upside
Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.
Our financial-history view of ISRG (ISRG) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
ISRG — frequently asked questions
Based on our latest analysis, ISRG looks meaningfully overvalued. The current price is $450 versus a composite fair-value midpoint of $255 (range $176–$337), which implies roughly 43.4% downside to the midpoint.
Our composite fair-value range for ISRG is $176–$337, with a midpoint of $255. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ISRG's archetype.
Our current rating for ISRG is Sell with a confidence score of 87/100. Sell. The 56% divergence from internal valuation cross-checks signals heavy market premium; intrinsic baseline valuation is $254.67. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ISRG are: Medtronic/J&J Capture 30% Market Share; Severe Hospital Capex Freeze; New Modality Disruption. The single biggest risk is Medtronic/J&J Capture 30% Market Share: Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.
Our current rating for ISRG is Sell, issued with a confidence score of 87/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($176–$337) versus the current price of $450.
ISRG is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ISRG.
